Q1 EPS Estimate for Evaxion Biotech A/S Boosted by Analyst

Evaxion Biotech A/S (NASDAQ:EVAX) – Investment analysts at Zacks Small Cap boosted their Q1 2025 earnings per share (EPS) estimates for Evaxion Biotech A/S in a note issued to investors on Wednesday, February 5th. Zacks Small Cap analyst B. Sorensen now forecasts that the company will earn ($0.75) per share for the quarter, up from their previous forecast of ($1.35). The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.43) per share. Zacks Small Cap also issued estimates for Evaxion Biotech A/S’s Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($1.49) EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.20 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.23 EPS and FY2026 earnings at $0.69 EPS.

Other equities analysts also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Evaxion Biotech A/S in a research note on Monday. Lake Street Capital dropped their price objective on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday.

Evaxion Biotech A/S Stock Performance

Evaxion Biotech A/S stock opened at $2.75 on Friday. Evaxion Biotech A/S has a 52 week low of $2.22 and a 52 week high of $23.70. The company’s 50 day moving average price is $4.59 and its two-hundred day moving average price is $10.48. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80.

Hedge Funds Weigh In On Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S as of its most recent filing with the Securities & Exchange Commission. 11.04% of the stock is owned by hedge funds and other institutional investors.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.